The pharmaceutical sector in Pakistan plays a vital role in providing essential healthcare products and services to the population.
It encompasses the production, import, export, distribution, and marketing of pharmaceutical products.
Pakistan has a large and growing pharmaceutical market, driven by a population of over 200 million people and increasing healthcare needs.
The market is valued at billions of dollars annually and has been experiencing steady growth over the years.
Key Players
Several multinational and domestic pharmaceutical companies operate in Pakistan, contributing to the sector's development.
Multinational companies like Pfizer, GlaxoSmithKline, and Novartis have a significant presence in the market.
Domestic companies such as Searle, Getz Pharma, and Abbott Pakistan are prominent players in the industry.
3. The pharmaceutical industry is
defined as the discovery,
development, and manufacture of
drugs and medications. It's
widespread, including research,
chemicals, and the regulation and
involvement of government agencies.
However, the characteristics of the
pharmaceutical industry differ by
region.
.
Introduction
4. Industry
Overview
01
Market size
Pharmaceutical industry in Pakistan is
worth USD 4.4 billion as of 2021
.
02
Growth rate
Industry growth rate is 7.5% annually
03
Competition
800 registered pharmaceutical companies
in Pakistan
04
Major player
Major players include GlaxoSmithKline,
Novartis, and Pfizer
5. Regulatory Environment
Drug Regulatory Authority of
Pakistan (DRAP) is the regulatory
authority for pharmaceuticals in
Pakistan
DRAP is responsible for regulating
registration, pricing, and quality of
drugs
Non-compliance with DRAP regulations can
result in fines and legal action
DRAP
6. Market Dynamics
Market growth rate
Pakistani
pharmaceutical market
is projected to grow at
a CAGR of 8.4% from
2021-2026
.
Major sector
Key therapeutic areas
include cardiovascular,
anti-infective, and
analgesics
Branded sector
Branded generics
account for 80% of the
market
7. Manufacturing
and Production
Pakistan has 786 licensed
manufacturing units for
pharmaceuticals
Manufacturing capacity is over
60 billion tablets and 12 billion
capsules annually
Pakistan also produces active
pharmaceutical ingredients
(APIs) for export
8. Research and Development
• Pakistan has over 180
research-based
pharmaceutical companies
• R&D expenditure accounts for
2.2% of industry revenue
• Major areas of research
include oncology,
cardiovascular disease, and
infectious diseases
9. Export Potential
Challenges in
exports
Challenges to exporting include
regulatory compliance, intellectual
property issues, and quality control
Major markets
Major export markets include
Afghanistan, Sri Lanka, and Vietnam
2020 exports
Pakistani pharmaceutical exports
were worth USD 215 million in 2020
10. Challenges faced by the industry include
counterfeit drugs, lack of investment, and
high cost of imported raw materials
1
Opportunities for growth include
developing biosimilars, expanding export
markets, and increasing investment in
R&D
2
2
1
4
2
3
Challenges and
Opportunities